Senators push for quicker generic drug access

by Henry C. Jackson

(AP)—Two senators want to do away with the agreements that pharmaceutical companies make with one another to keep lower-priced generic copies of brand-name drugs off the market.

Democratic Sen. Amy Klobuchar of Minnesota and Republican Charles Grassley of Iowa say such "pay-for-delay" deals force consumers to pay higher prices for critical drugs. Their bill would make such agreements illegal unless the companies can prove in court that they aren't anti-competitive.

Grassley says Congress, in his words, "should be doing all we can to see that the American consumer has access to lower-priced drugs as soon as possible."

Representatives of the tell a Senate antitrust subcommittee chaired by Klobuchar that the agreements sometimes shorten the time for to reach the market, particularly in patent disputes.

5 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

US: 'Pay to delay' generic drugs can be illegal (Update)

Jun 17, 2013

The Supreme Court ruled Monday that deals between pharmaceutical corporations and their generic drug competitors, which government officials say keep cheaper forms of medicine off the market, can be sometimes be illegal and ...

High court weighs drug companies' generics policy

Mar 25, 2013

(AP)—The Supreme Court is struggling with whether it should stop pharmaceutical corporations from paying generic drug competitors to delay releasing their cheaper versions of brand-name drugs.

Research shows moves to ban pay-to-delay deals are justified

Jun 18, 2013

Controversial deals that delay generic versions of drugs coming onto the market can lead to consumers paying significantly more for some treatments, according to new research by an academic from the University of East Anglia ...

EU fines pharma firms over generics delay (Update)

Jun 19, 2013

(AP)—The European Union has fined Danish pharmaceuticals multinational Lundbeck and several other producers a combined 146 million euros ($195 million) for delaying the market entry of cheaper generic alternatives ...

Court: Can drug companies pay to delay generics?

Mar 24, 2013

(AP)—Federal regulators are pressing the Supreme Court to stop big pharmaceutical corporations from paying generic drug competitors to delay releasing their cheaper versions of brand-name drugs. They argue ...

Recommended for you

Big cities take aim at prescription painkillers

8 hours ago

Some of the nation's largest cities are ratcheting up their criticism of prescription painkillers, blaming the industry for a wave of addiction and overdoses that have ravaged their communities and busted local budgets.

World Health Organization policy improves use of medicines

9 hours ago

In this issue of PLOS Medicine, Kathleen Holloway from WHO and David Henry (University of Toronto, Canada) evaluated data on reported adherence to WHO essential medicines practices and measures of quality use of medicines from 5 ...

Vaccine proves effective against deadly Middle East virus

Sep 15, 2014

(Medical Xpress)—A vaccine developed by an international team of scientists led by the University of Pittsburgh School of Medicine successfully protects mice against a contagious and deadly virus spreading across the Middle ...

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

VOR
not rated yet Jul 24, 2013
We dont just need socialized healthcare. We need socialized drug development. It wouldn't be such a big leap, a waste, or a killer of innovation. The 'bottom line' inescapable, irrefutable truth is that drugs-for-profit will never have the patients' health as the only priority, and sometimes not even the priority. This is reflected over and over again in many ways including biased trials/conflicts of interest, the hiding/downplaying of dangerous results to continue to market, and advertising-derived (excess) demand. Money should NOT be at stake when our health is. The amount of R&D $ put into a drug should have no influence on it's acceptance. And money should be allocated to test/discover what are likely many untapped (because they can't be patented, or are simpler or legacy drugs that were never tested for alternate indictation etc) effective treatments.